Pay in 4 interest-free payments of $36.25 Learn more
Ships within 48 hours · Estimated delivery Aug 6 - Aug 11
54(2):635-54
CUDC-907 was orally dosed to mice at 100 mg/kg or intravenously dosed at 50 mg/kg once per day in the xenograft tumor model of SU-DHL4 (DLBCL) and A549 (NSCLC)
Formula: C17H20N6O4S
but highly potent against ROCK1 (IC50=100 nM)
Tsisanova E
GGTI-298 TFA - CAS# 1217457-86-7 60002 54(2):635-54GGTI 298 TFA, CAS No. 1217457 86 7, is a potent geranylgeranyltransferase I (GGTase I) inhibitor with potential antitumor actrivity. GGTI 298 disrupts MAP kinase activation and G(1) S transition in Ki Ras overexpressing transformed adrenocortical cells. GGTI 298 induces hypophosphorylation of retinoblastoma and partner switching of cyclin dependent kinase inhibitors. A potential mechanism for GGTI 298 antitumor activity. GGTI 298 arrests human tumor
US$ 1639.50
US$ 1550.00